ES2159529T3 - Anticuerpos monoclonales humanos anti-tnf alfa. - Google Patents

Anticuerpos monoclonales humanos anti-tnf alfa.

Info

Publication number
ES2159529T3
ES2159529T3 ES94102560T ES94102560T ES2159529T3 ES 2159529 T3 ES2159529 T3 ES 2159529T3 ES 94102560 T ES94102560 T ES 94102560T ES 94102560 T ES94102560 T ES 94102560T ES 2159529 T3 ES2159529 T3 ES 2159529T3
Authority
ES
Spain
Prior art keywords
human monoclonal
tnf alpha
monoclonal antibodies
human
binds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94102560T
Other languages
English (en)
Other versions
ES2159529T5 (es
Inventor
Petra Boyle
Gayle D Wetzel
Kenneth J Lembach
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Bayer Corp
Original Assignee
Bayer AG
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26701860&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2159529(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer AG, Bayer Corp filed Critical Bayer AG
Publication of ES2159529T3 publication Critical patent/ES2159529T3/es
Application granted granted Critical
Publication of ES2159529T5 publication Critical patent/ES2159529T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pyrane Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

ANTICUERPOS MONOCLONALES HUMANOS (MABS) QUE SE UNEN A TNFALFA HUMANO. SE DESCRIBEN ANTICUERPOS E ISOTIPOS IGG Y IGM. EL REFERIDO ANTICUERPO MONOCLONAL HUMANO SE CONOCE COMO B5 ( F78 HUMANO EN EL FORMATO ELISA CON UNA LEY COMPARABLE A LA TRINEUTRALIZACION DE ALTA AFINIDAD DE MABS DE RATON. TAMBIEN ENLAZA AL TNFALFA CELULAR SUPERFICIAL Y PREVIENE LA SECRECION DE TNFALFA POR LAS LINEAS CELULARES HUMANAS MONOCITICAS.
ES94102560T 1993-03-05 1994-02-21 Anticuerpos monoclonales humanos anti-tnf alfa. Expired - Lifetime ES2159529T5 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US2695793A 1993-03-05 1993-03-05
US26957 1993-03-05
US14506093A 1993-10-29 1993-10-29
US145060 1993-10-29

Publications (2)

Publication Number Publication Date
ES2159529T3 true ES2159529T3 (es) 2001-10-16
ES2159529T5 ES2159529T5 (es) 2011-03-09

Family

ID=26701860

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94102560T Expired - Lifetime ES2159529T5 (es) 1993-03-05 1994-02-21 Anticuerpos monoclonales humanos anti-tnf alfa.

Country Status (11)

Country Link
US (1) US5654407A (es)
EP (1) EP0614984B2 (es)
JP (2) JP4225519B2 (es)
AT (1) ATE204299T1 (es)
CA (1) CA2116888C (es)
DE (2) DE122009000074I1 (es)
DK (1) DK0614984T4 (es)
ES (1) ES2159529T5 (es)
LU (1) LU91661I2 (es)
NL (1) NL300421I2 (es)
PT (1) PT614984E (es)

Families Citing this family (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672347A (en) * 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
IL73883A (en) * 1984-12-20 1990-12-23 Yeda Res & Dev Monoclonal antibodies against tnf-alpha,hybridomas producing them and method for the purification of tnf-alpha
US5959087A (en) * 1989-08-07 1999-09-28 Peptide Technology, Ltd. Tumour necrosis factor binding ligands
WO1991002078A1 (en) 1989-08-07 1991-02-21 Peptide Technology Ltd Tumour necrosis factor binding ligands
US20030225254A1 (en) * 1989-08-07 2003-12-04 Rathjen Deborah Ann Tumour necrosis factor binding ligands
US6713610B1 (en) * 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
GB9109645D0 (en) * 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US20040120952A1 (en) * 2000-08-07 2004-06-24 Centocor, Inc Anti-TNF antibodies and peptides of human tumor necrosis factor
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US20050255104A1 (en) * 1993-01-29 2005-11-17 Centocor, Inc. Methods of treating psoriasis using anti-TNF receptor fusion proteins
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
HU228630B1 (en) * 1996-02-09 2013-04-29 Abbott Biotech Ltd Use of human anti bodies that bind human tnf-alpha and process for inhibiting of human tnf-alpha activity
AU2013257402B2 (en) * 1996-02-09 2014-02-20 Abbvie Biotechnology Ltd Human antibodies that bind human TNFalpha
AU2013203420B2 (en) * 1996-02-09 2014-02-20 Abbvie Biotechnology Ltd Human antibodies that bind human TNFalpha
AU2012261708B2 (en) * 1996-02-09 2014-02-20 Abbvie Biotechnology Ltd Human antibodies that bind human TNFalpha
EP2314625B1 (en) * 1996-12-03 2014-05-07 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
US6395273B1 (en) 1998-06-10 2002-05-28 Promega Corporation Prevention and treatment of inflammatory bowel disease
US7494652B1 (en) 1998-06-10 2009-02-24 Promega Corporation Treatment of sepsis
PT1107996E (pt) 1998-08-28 2002-10-31 Genentech Inc Anticorpos humanos anti-factor ix/ixa
PT1159003E (pt) * 1999-03-02 2011-02-22 Centocor Inc Anti-tnf alfa na terapêutica da asma resistente a esteróides
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
WO2001043773A1 (en) * 1999-12-14 2001-06-21 Genentech, Inc. Tnf-alpha antagonist and lfa-1 antagonist for treating lfa-1 or tnf-alpha mediated disorder
US20060018907A1 (en) * 2000-08-07 2006-01-26 Centocor, Inc. Anti-TNF antibodies and peptides of human tumor necrosis factor
UA81743C2 (uk) * 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
US20110195063A1 (en) * 2000-08-07 2011-08-11 Centocor, Inc. Methods of Treating Ankylosing Spondylitis Using Anti-TNF Antibodies and Peptides of Human Tumor Necrosis Factor
US20050249735A1 (en) * 2000-08-07 2005-11-10 Centocor, Inc. Methods of treating ankylosing spondylitis using anti-TNF antibodies and peptides of human tumor necrosis factor
US20090081234A1 (en) * 2000-08-07 2009-03-26 George Heavner Anti-tnf antibodies, compositions, methods and uses for treatment of depression and related conditions
CA2868614A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
ATE464068T1 (de) 2001-06-26 2010-04-15 Amgen Fremont Inc Antikörper gegen opgl
US20050271663A1 (en) * 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
TWI327597B (en) 2001-08-01 2010-07-21 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
US20030206898A1 (en) 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
US20040009172A1 (en) * 2002-04-26 2004-01-15 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
MXPA05000815A (es) * 2002-07-19 2005-04-28 Abbott Biotech Ltd Tratamiento de trastornos relacionados con tnfa.
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
AU2003265361A1 (en) * 2002-08-28 2004-03-19 Pharmacia Corporation Stable ph optimized formulation of a modified antibody
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
US9320792B2 (en) 2002-11-08 2016-04-26 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
WO2004041865A2 (en) 2002-11-08 2004-05-21 Ablynx N.V. Stabilized single domain antibodies
US20060034845A1 (en) 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
WO2004050683A2 (en) * 2002-12-02 2004-06-17 Abgenix, Inc. Antibodies directed to tumor necrosis factor and uses thereof
EP1578782A4 (en) 2002-12-30 2007-09-12 Amgen Inc COSTIMULATING FACTORIAL THERAPY
US7101978B2 (en) * 2003-01-08 2006-09-05 Applied Molecular Evolution TNF-α binding molecules
US20040185047A1 (en) * 2003-03-21 2004-09-23 Jill Giles-Komar Anti- TNF antibodies, compositions, methods and uses
EP1460088A1 (en) * 2003-03-21 2004-09-22 Biotest AG Humanized anti-CD4 antibody with immunosuppressive properties
US7435799B2 (en) * 2004-01-08 2008-10-14 Applied Molecular Evolution TNF-α binding molecules
TW201705980A (zh) 2004-04-09 2017-02-16 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
US20060228753A1 (en) * 2004-07-12 2006-10-12 Andrew Levy Methods of detecting a phenotype of a polymorphic protein
WO2006041970A2 (en) * 2004-10-08 2006-04-20 Abbott Biotechnology Ltd. Treatment of respiratory syncytial virus (rsv) infection
US7645450B2 (en) * 2004-12-29 2010-01-12 Yuhan Corporation Humanized antibody specific for tumor necrosis factor-alpha
CN102961746B (zh) 2005-05-16 2016-06-15 艾伯维生物技术有限公司 TNFα抑制剂治疗腐蚀性多关节炎的用途
DK2390267T3 (da) 2005-06-07 2013-08-26 Esbatech A Novartis Co Llc Stabile og opløselige antistoffer, der hæmmer TNF(alfa)
DE602006014691D1 (de) * 2005-08-02 2010-07-15 Xbiotech Inc DIAGNOSE, BEHANDLUNG UND PRÄVENTION VON GEFÄSSERKRANKUNGEN MITTELS IL-1alpha-AUTOANTIKÖRPERN
US20070041905A1 (en) * 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
CA2621363C (en) * 2005-09-13 2015-07-07 National Research Council Of Canada Methods and compositions for modulating tumor cell activity
JP4861019B2 (ja) * 2006-01-31 2012-01-25 独立行政法人科学技術振興機構 ヒトＴＮＦ−αに対する抗体酵素およびその利用
CA2911000A1 (en) 2006-04-05 2007-10-18 Min W. Wan Antibody purification
US20080118496A1 (en) * 2006-04-10 2008-05-22 Medich John R Uses and compositions for treatment of juvenile rheumatoid arthritis
EP2666472A3 (en) 2006-04-10 2014-04-02 Abbott Biotechnology Ltd Uses and compositions for treatment of psoriatic arthritis
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
EP2010214A4 (en) 2006-04-10 2010-06-16 Abbott Biotech Ltd USES AND COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
US20090317399A1 (en) * 2006-04-10 2009-12-24 Pollack Paul F Uses and compositions for treatment of CROHN'S disease
US20080131374A1 (en) * 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
US20110008282A1 (en) * 2006-05-15 2011-01-13 Xbiotech, Inc. IL-1alpha immunization induces autoantibodies protective against atherosclerosis
CN102580086A (zh) * 2006-05-22 2012-07-18 埃克斯生物科技公司 使用抗IL-1α抗体治疗癌症
CN104524567A (zh) * 2007-01-16 2015-04-22 阿布维公司 用于治疗银屑病的方法
NZ580530A (en) * 2007-06-06 2012-04-27 Domantis Ltd Anti vegf polypeptides, antibody variable domains and antagonists
WO2008154543A2 (en) 2007-06-11 2008-12-18 Abbott Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis
US20090038182A1 (en) * 2007-08-09 2009-02-12 Lans Maris J Footwear with built-in scale
US8969024B2 (en) 2007-08-28 2015-03-03 Abbvie Biotechnology Ltd Compositions and methods comprising binding proteins for adalimumab
KR20100120289A (ko) 2008-01-15 2010-11-15 애보트 게엠베하 운트 콤파니 카게 분말상 단백질 조성물 및 이의 제조 방법
US8883155B2 (en) * 2008-01-28 2014-11-11 The Regents Of The University Of California Methods for treating hematopoietic malignancies
KR20100135257A (ko) * 2008-03-13 2010-12-24 바이오테스트 아게 질병 치료제
CA2718191C (en) * 2008-03-13 2018-05-15 Biotest Ag Agent for treating disease
AU2009224690B2 (en) * 2008-03-13 2014-10-09 Biotest Ag Agent for treating disease
KR20100126515A (ko) 2008-03-18 2010-12-01 아보트 러보러터리즈 건선의 치료방법
CN103656638B (zh) * 2008-05-30 2016-04-27 埃克斯生物科技公司 白细胞介素-1α抗体及使用方法
WO2009155723A2 (en) * 2008-06-25 2009-12-30 Esbatech, An Alcon Biomedical Research Unit Llc STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFα
CN102209557A (zh) * 2008-09-12 2011-10-05 埃克斯生物科技公司 靶向病原性单核细胞
PT2341937E (pt) * 2008-09-29 2015-02-18 Biotest Ag Composição para tratamento de doença
US8415291B2 (en) * 2008-10-31 2013-04-09 Centocor Ortho Biotech Inc. Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses
US20100172862A1 (en) * 2008-11-28 2010-07-08 Abbott Laboratories Stable antibody compositions and methods of stabilizing same
US8349325B2 (en) 2008-12-23 2013-01-08 Abbott Laboratories Soluble FMS-like tyrosine kinase-1 (sFLT-1) antibody and related composition, kit, methods of using, and materials and method for making
WO2011032148A1 (en) * 2009-09-14 2011-03-17 Abbott Laboratories Methods for treating psoriasis
DK2504363T3 (da) 2009-11-24 2019-07-29 Alethia Biotherapeutics Inc Anti-clusterin-antistoffer og antigenbindende fragmenter og deres anvendelse til reducering af tumorvolumen
GB0920944D0 (en) 2009-11-30 2010-01-13 Biotest Ag Agents for treating disease
US8846397B2 (en) 2010-01-20 2014-09-30 Merck Sharp & Dohme Corp. Immunoregulation by anti-ILT5 antibodies and ILT5-binding antibody fragments
CA2787783A1 (en) 2010-01-20 2011-07-28 Tolerx, Inc. Anti-ilt5 antibodies and ilt5-binding antibody fragments
CN102167741B (zh) * 2010-02-25 2014-05-14 上海百迈博制药有限公司 一种全人源抗TNF-α单克隆抗体、其制备方法及用途
US20110229921A1 (en) 2010-03-18 2011-09-22 Abbott Laboratories METHODS OF ASSAYING URINARY NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN (uNGAL) IN THE PROGNOSIS OF CADAVERIC KIDNEY TRANSPLANT FUNCTION IN A PATIENT, INCLUDING A PATIENT DIAGNOSED WITH DELAYED GRAFT FUNCTION (DGF), A METHOD OF ASSAYING uNGAL IN THE ASSESSMENT OF RISK OF DGF IN A PATIENT DIAGNOSED WITH EARLY GRAFT FUNCTION (EGF), AND RELATED KITS
KR102167261B1 (ko) 2010-06-18 2020-10-20 엑스바이오테크, 인크. 관절염 치료
WO2011163558A1 (en) 2010-06-25 2011-12-29 Abbott Laboratories Materials and methods for assay of anti-hepatitis c virus (hcv) antibodies
KR102314003B1 (ko) 2010-08-23 2021-10-19 얀센 바이오테크 인코포레이티드 종양성 질병들에 대한 치료
UY33679A (es) 2010-10-22 2012-03-30 Esbatech Anticuerpos estables y solubles
US20120115244A1 (en) 2010-11-09 2012-05-10 Abbott Laboratories Materials and methods for immunoassay of pterins
CN102539778A (zh) * 2010-12-24 2012-07-04 北京义翘神州生物技术有限公司 一种检测人肿瘤坏死因子-α的酶联免疫试剂盒
US20140051586A1 (en) * 2011-01-25 2014-02-20 Ignacio Pino High-throughput methods to produce, validate and characterize mmabs
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
ES2695102T3 (es) 2011-09-23 2019-01-02 Xbiotech Inc Tratamiento para la caquexia
US8993248B2 (en) 2011-12-31 2015-03-31 Abbott Laboratories Truncated human vitamin D binding protein and mutation and fusion thereof and related materials and methods of use
MX2014010164A (es) 2012-02-22 2014-11-25 Alethia Biotherapeutics Inc Co-uso de un inhibidor de clusterina con un inhibidor de egfr para tratar cancer.
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
KR20150043523A (ko) 2012-09-02 2015-04-22 애브비 인코포레이티드 단백질 불균일성의 제어 방법
US9545441B2 (en) 2012-09-18 2017-01-17 Xbiotech, Inc. Treatment of diabetes
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
EP2968550B1 (en) 2013-03-14 2018-11-14 Ffe Therapeutics LLC Compositions and methods for treating angiogenesis-related disorders
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
EP3247728B1 (en) 2015-01-20 2020-04-15 IGM Biosciences, Inc. Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof
US10465003B2 (en) 2016-02-05 2019-11-05 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
KR20240038146A (ko) 2017-01-30 2024-03-22 얀센 바이오테크 인코포레이티드 활성 건선성 관절염의 치료를 위한 항-tnf 항체, 조성물, 및 방법
CN110418652A (zh) 2017-02-07 2019-11-05 詹森生物科技公司 用于治疗活动性强直性脊柱炎的抗tnf抗体、组合物和方法
MX2019009798A (es) 2017-02-16 2020-01-30 Xbiotech Inc Tratamiento de la hidradenitis supurativa.
CN107903323B (zh) * 2017-11-15 2020-04-17 中国药科大学 抗hTNF-α全人源抗体及其用途
MX2021014302A (es) 2019-05-23 2022-01-04 Janssen Biotech Inc Metodo para tratar la enfermedad inflamatoria del intestino con una terapia de combinacion de anticuerpos contra il-23 y tnf alfa.
WO2020254861A1 (en) 2019-06-19 2020-12-24 Ovatrition Ltd. Antibody-mediated neutralization of beta-lactamases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2083688A (en) † 1987-07-09 1989-02-13 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Preparation of human monoclonal antibodies of selected specificity and isotypes
JPH05501351A (ja) * 1989-08-16 1993-03-18 カイロン　コーポレイション プロホルモンタンパク質に対する開裂部位阻止抗体及びその使用
GB8921123D0 (en) * 1989-09-19 1989-11-08 Millar Ann B Treatment of ards
GB9109645D0 (en) † 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
DE69321909T2 (de) † 1992-08-28 1999-04-01 Bayer Ag Verwendung von monoklonalen Anti-TNF-Antikörpern für die Behandlung von bakteriellen Meningitiden

Also Published As

Publication number Publication date
EP0614984A2 (en) 1994-09-14
LU91661I2 (fr) 2010-05-10
PT614984E (pt) 2001-12-28
CA2116888A1 (en) 1994-09-06
NL300421I2 (nl) 2010-04-01
ATE204299T1 (de) 2001-09-15
JP2009046487A (ja) 2009-03-05
DE69427928T3 (de) 2012-05-10
DK0614984T3 (da) 2001-11-05
DE69427928D1 (de) 2001-09-20
DE69427928T2 (de) 2001-11-29
EP0614984B2 (en) 2010-11-03
EP0614984A3 (en) 1995-05-24
CA2116888C (en) 2003-08-12
US5654407A (en) 1997-08-05
ES2159529T5 (es) 2011-03-09
JPH06319587A (ja) 1994-11-22
JP4225519B2 (ja) 2009-02-18
NL300421I1 (nl) 2010-01-04
DE122009000074I1 (de) 2011-12-01
DK0614984T4 (da) 2010-12-20
EP0614984B1 (en) 2001-08-16

Similar Documents

Publication Publication Date Title
ES2159529T3 (es) Anticuerpos monoclonales humanos anti-tnf alfa.
IL83113A (en) Bifunctional antibodies having antigen specificity for fc receptor and for an epitope of a target cell
BR9507594B8 (pt) Anticorpo monoclonal com scfv humanizado, molécula de ácido nucleico recombinante e proteína recombinante.
DE69628652D1 (de) Vegf-verwandtes protein
FI834530A (fi) Affinitetsreningsfoerfarande medelst monoklonala anti-kroppar.
ZA874558B (en) Monoclonal antibodies to unreduced,nonenzymatically-glycated proteins
KR880700823A (ko) 사이토메갈로 바이러스에 대한 사람.모노클로날 항체와 그 제조방법
ATE375802T1 (de) Ccr5 antikörper pa14
DK0576439T3 (da) Monoklonalt antistof mod LPS-kerne
Fukuma et al. Human thyroglobulin autoantibodies of subclasses IgG2 and IgG4 bind to different epitopes on thyroglobulin.
ATE229080T1 (de) Monoklonale antikörper gegen ck-mb
Ohlson et al. High-performance liquid affinity chromatographic separation of mouse monoclonal antibodies with protein A silica
Sugiura et al. Production of monoclonal antibodies to six isotypes of horse immunoglobulin
Würzner et al. Determination of the epitope specificities of monoclonal antibodies using unprocessed supernatants of hybridoma cultures
Persson Preparation of human sera containing one single IgG subclass using affinity chromatography
Inouye et al. Preparation of F (ab′) 2μ fragments from rat IgM monoclonal antibodies and their application to the enzyme immunoassay of mouse interleukin-6
Storch et al. A new and rapid method for immunoglobulin class and subclass determination of mouse monoclonal antibodies using a solid-phase immunoradiometric assay
Ćirić et al. Effect of valency on binding properties of the antihuman IgM monoclonal antibody 202
Takeo et al. Studies on heterogeneity of anti-DNP antibody by means of two-dimensional affinity electrophoresis
Nilson The bacterial cell wall molecules protein G and protein L: Characterization and use of their immunoglobulin binding properties.
McBride et al. Production and characterization of monoclonal antibodies directed against guinea pig IgG subclasses
Jones et al. The isotype and specificity of antiglobulins in BALB/c mice.
JPH04271795A (ja) インターロイキン５の微量定量
Lombardero et al. Monoclonal antibodies to distinct epitopes on human IgA and their use to IgA determination
Srikumaran Monoclonal bovine immunoglobulins and their antisera: production isolation and characterization.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 614984

Country of ref document: ES